Literature DB >> 11898892

Clinical outcomes of critical illness polyneuropathy.

Sandra L Kane1, Joseph F Dasta.   

Abstract

It is often difficult to isolate the origin of acute weakness in the critically ill population because of multiple etiologies. Aminoglycosides, corticosteroids, and neuromuscular blockers frequently are implicated as the source of acute weakness. Recently, critical illness polyneuropathy (CIP), a syndrome of unknown etiology, was added to the differential diagnosis. The frequency of CIP is approximately 70% in patients with sepsis. Early studies of CIP, which were mostly retrospective, underestimated its frequency due to the complexity of the diagnosis and unfamiliarity with the syndrome. Prospective studies have explored the causality and clinical outcomes of CIP Clinical outcomes of patients with CIP include difficulty weaning from mechanical ventilation, increased length of stay, prolonged recovery, and an overall mortality rate of 26-71%. The association of CIP with sepsis, multiorgan failure, and drugs is still unclear.

Entities:  

Mesh:

Year:  2002        PMID: 11898892     DOI: 10.1592/phco.22.5.373.33199

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  3 in total

1.  Usefulness of a clinical diagnosis of ICU-acquired paresis to predict outcome in patients with SIRS and acute respiratory failure.

Authors:  Anna-Giulia Brunello; Matthias Haenggi; Oliver Wigger; Francesca Porta; Jukka Takala; Stephan M Jakob
Journal:  Intensive Care Med       Date:  2009-09-16       Impact factor: 17.440

2.  Critical illness polyneuropathy (CIP) in neurological early rehabilitation: clinical and neurophysiological features.

Authors:  Simone B Schmidt; Jens D Rollnik
Journal:  BMC Neurol       Date:  2016-12-15       Impact factor: 2.474

3.  Polyneuropathy and myopathy in the elderly.

Authors:  R E Dalton; R S Tripathi; E E Abel; D S Kothari; M S Firstenberg; S P Stawicki; T J Papadimos
Journal:  HSR Proc Intensive Care Cardiovasc Anesth       Date:  2012
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.